Combination of mtor inhibitors and pi3-kinase inhibitors, and uses thereof

Abstract

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

1 . A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of the mTOR inhibitor: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of the PI3-kinase α inhibitor: 
       
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof: wherein said cancer is renal cell carcinoma or endometrial cancer. 
       
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein said cancer is endometrial cancer. 
     
     
         4 . The method of  claim 1 , wherein said cancer is renal cell carcinoma. 
     
     
         5 - 18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the PI3-kinase α inhibitor and/or the mTOR inhibitor are administered parenterally, orally, intraperitoneally, intravenously, intraarterially, transdermally, intramuscularly, liposomally, via local delivery by catheter or stent, subcutaneously, intraadiposally, or intrathecally. 
     
     
         20 . The method of  claim 1 , wherein the PI3-kinase α inhibitor and/or the mTOR inhibitor are co-administered to the subject in the same formulation. 
     
     
         21 . The method of  claim 1 , wherein the PI3-kinase α inhibitor and/or the mTOR inhibitor are co-administered to the subject in different formulations. 
     
     
         22 - 38 . (canceled) 
     
     
         39 . The method of  claim 1 , wherein the PI3-kinase α inhibitor and/or the mTOR inhibitor are administered orally. 
     
     
         40 . The method of  claim 1 , wherein the PI3-kinase α inhibitor and/or the mTOR inhibitor are administered simultaneously or sequentially.